Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Tilray Brands, Inc. TLRY

Alternate Symbol(s):  T.TLRY

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis business, Distribution business, Beverage alcohol business and Wellness business. The Cannabis business segment is engaged in the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. The... see more

NDAQ:TLRY - Post Discussion

Tilray Brands, Inc. > Tipranks say Tilray losing the rest of its medmen investment
View:
Post by Keeler on Apr 14, 2024 11:02am

Tipranks say Tilray losing the rest of its medmen investment

Tilray’s Investment in Jeopardy: MedMen’s Troubles Threaten $32K Ce 

 

 

Tilray (TLRY) has disclosed a new risk, in the Debt & Financing category.

Tilray faces considerable financial risk regarding its investment in MedMen’s secured convertible notes, particularly after MedMen’s recent executive changes and the appointment of a chief restructuring officer. The potential restructuring or liquidation of MedMen might substantially affect the recoverability of the $32 million carrying value recorded by Tilray. With MedMen’s operations and assets at risk, the security interests that underpin Tilray’s investment could prove difficult to enforce, especially outside of federal bankruptcy law jurisdictions. Such uncertainties raise the specter of significant impairments to Tilray’s financial statements, potentially impacting the overall investment portfolio’s value detrimentally.

The average TLRY stock price target is $2.30, implying 13.86% upside potential.

 

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities